Rituximab (anti-CD20)

Screening: how T1D is caught before symptoms

T1D is now understood as a staged disease you can see coming years in advance. A 2015 consensus from JDRF, the Endocrine Society and the American Diabetes Association defined three stages from a simple blood test: Stage 1 is two or more islet autoantibodies with normal blood sugar; Stage 2 adds dysglycemia (blood sugar starting to drift) but still no symptoms; Stage 3 is clinical diabetes — the symptoms most people are diagnosed at.³ Once two or more autoantibodies are present, the pooled cohort read here reached about 70% progression at 10 years (lifetime certainty not established in the sources read), which is what makes a single antibody screen so predictive.³

You can screen anyone — relatives of people with T1D (higher baseline risk) or the general population. Large general-population programs such as Germany's Fr1da study screened, as reported in the cited press release (release body not re-read in-session), more than 90,000 young children for a few tens of dollars each.⁶ The payoff, as reported in that release, is concrete: finding people early and monitoring them sharply cuts the rate of diabetic ketoacidosis (DKA) — the dangerous, sometimes fatal metabolic crisis that strikes many at diagnosis — because families know what is coming instead of being ambushed.⁶ Early detection is also the gateway to every therapy on this page: you cannot offer a pre-symptomatic treatment to someone you never identified.

The therapy: borrowing a cancer drug

Rituximab is not a diabetes drug. It is a chimeric monoclonal antibody that targets CD20, a marker on B lymphocytes, and destroys those cells — and it is approved for lymphoma, leukemia, rheumatoid arthritis and several other autoimmune conditions (full approval list as given in the cited StatPearls page, not re-verified here), but not for T1D.⁴ Researchers repurposed it on a hunch: T1D was long blamed almost entirely on T cells, but B cells help present the targets that T cells attack.

The mechanism, and what the trial showed. In a TrialNet Phase 2 randomized trial (NCT00279305), 87 people aged 8–40 newly diagnosed with T1D — i.e. already at Stage 3 — got four weekly infusions of rituximab or placebo.¹ At one year, the rituximab group held onto more of their own insulin production: mean stimulated C-peptide was higher (exact means are full-text figures beyond the abstract read here), with lower HbA1c and lower insulin needs.¹ That was a genuinely important result — proof that depleting B cells could bend the disease, and therefore that B cells are part of the attack, not bystanders.¹

But the effect faded. Following the same people out to 30 months, the decline in insulin production resumed once B cells repopulated (back to baseline by about 18 months); the curves ran parallel, simply shifted by roughly 8.2 months, and by the end the two groups looked the same on insulin and HbA1c.² The authors' honest conclusion: rituximab delays the fall in C-peptide but does not fundamentally alter the underlying disease.² Crucially, it was never tested as true prevention — only at diagnosis — so it does not delay onset at all.

Safety, stage and access. Side effects were dominated by first-infusion reactions (rash, itching, nausea, low blood pressure) in 93% of treated patients (rate and symptom detail as reported in the full trial paper, beyond the abstract read here), mostly mild and fading with later infusions; there was no excess of infections or low neutrophils, though B-cell depletion is described here as blunting responses to vaccines (not verified in the sources read).¹ It is described here as cheap and globally available — especially as biosimilars (availability and price not verified in the sources read) — but because it carries no T1D approval, any use is investigational or off-label, never a standard prescription.⁴

What's coming for it

Rituximab's real legacy may be as a combination partner. TrialNet's T1D RELAY trial (NCT03929601) is testing rituximab-pvvr (a biosimilar) followed by abatacept — a different immune brake — in newly diagnosed patients, on the theory that knocking down B cells first and then dampening T-cell co-stimulation could produce the durable effect a single drug never did, with results expected around 2027.⁵ The single-agent story is over; the combination story is just starting.